AGEN,
Item 3.02 Unregistered Sale of Equity Securities.
On August 3, 2009, Antigenics Inc. (the "Company") entered into a Securities Purchase Agreement (the "Agreement") pursuant to which the Company issued and sold to certain investors shares of the Company's common stock, par value $0.01 per share, and warrants to purchase the Company's common stock for an aggregate purchase price of approximately $10 million. Under the terms of the Agreement, the investors in the private placement purchased 4,385,965 shares of common stock at $2.28 per share, and also received six-month warrants to purchase up to 2,192,982 additional shares of common stock at an exercise price of $2.31 per share and four-year warrants to purchase up to 1,973,685 additional shares of common stock at an exercise price of $2.50 per share. The warrants are not exercisable for the first six months following the closing. The form of the six-month purchase warrant, form of the four-year purchase warrant and the Agreement are attached to this report as Exhibits 4.1, 4.2 and 10.1, respectively, and are incorporated herein by reference. |